{"id":43023,"date":"2025-10-10T16:44:44","date_gmt":"2025-10-10T08:44:44","guid":{"rendered":"https:\/\/flcube.com\/?p=43023"},"modified":"2025-10-10T16:44:45","modified_gmt":"2025-10-10T08:44:45","slug":"jw-cayman-therapeutics-secures-nmpa-acceptance-for-carteyva-introducing-in%e2%80%91house-lentiviral-vector-production","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43023","title":{"rendered":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production"},"content":{"rendered":"\n<p>JW (Cayman) Therapeutics Co. Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2126:HKG\">HKG: 2126<\/a>) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for <strong>Carteyva<\/strong> (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Acceptance<\/strong> \u2013 The supplementary application confirms that Carteyva, an autologous anti\u2011CD19 CAR\u2011T cell therapy, can be manufactured using JW\u2019s newly developed lentiviral vector <strong>JWLV011<\/strong>.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011China Category\u202f1 Biologic<\/strong> \u2013 Carteyva is the first CAR\u2011T product approved as a Category\u202f1 biologics therapy in China, covering relapsed or refractory large B\u2011cell lymphoma (r\/r\u00a0LBCL), follicular lymphoma (r\/r\u00a0FL), and mantle cell lymphoma (r\/r\u00a0MCL).<\/li>\n\n\n\n<li><strong>Supply\u2011Chain Stabilization<\/strong> \u2013 By shifting from overseas lentiviral vector suppliers to the in\u2011house JWLV011 platform, JW Therapeutics aims to reduce raw\u2011material costs, enhance production scalability, and improve quality control.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h3>\n\n\n\n<p>A Phase\u202f2 single\u2011arm study demonstrated that Carteyva produced with JWLV011 is <strong>clinically comparable<\/strong> to products manufactured with traditional lentiviral vectors, supporting the safety and efficacy profile that underpins the NMPA\u2019s acceptance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-impact\">Strategic Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Expansion<\/strong> \u2013 The new manufacturing route positions JW Therapeutics to meet growing demand for CAR\u2011T therapies in China and abroad.<\/li>\n\n\n\n<li><strong>Cost Optimization<\/strong> \u2013 In\u2011house vector production is projected to lower per\u2011dose costs, potentially expanding patient access.<\/li>\n\n\n\n<li><strong>Innovation Leadership<\/strong> \u2013 The successful integration of a proprietary lentiviral vector platform reinforces JW\u2019s reputation as a pioneer in next\u2011generation immunotherapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900583_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025100900583_c.\"><\/object><a id=\"wp-block-file--media-ba9e6a75-2ebf-49a3-8cec-65e8458a3f9b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900583_c.pdf\">2025100900583_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900583_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ba9e6a75-2ebf-49a3-8cec-65e8458a3f9b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43025,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[21,1165,321],"class_list":["post-43023","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-car-t","tag-hkg-2126","tag-jw-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43023\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production\" \/>\n<meta property=\"og:description\" content=\"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43023\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T08:44:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T08:44:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production\",\"datePublished\":\"2025-10-10T08:44:44+00:00\",\"dateModified\":\"2025-10-10T08:44:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023\"},\"wordCount\":285,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1007.webp\",\"keywords\":[\"CAR-T\",\"HKG: 2126\",\"JW Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43023#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43023\",\"name\":\"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1007.webp\",\"datePublished\":\"2025-10-10T08:44:44+00:00\",\"dateModified\":\"2025-10-10T08:44:45+00:00\",\"description\":\"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43023\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1007.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1007.webp\",\"width\":1080,\"height\":608,\"caption\":\"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43023#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production - Insight, China&#039;s Pharmaceutical Industry","description":"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43023","og_locale":"en_US","og_type":"article","og_title":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production","og_description":"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.","og_url":"https:\/\/flcube.com\/?p=43023","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-10T08:44:44+00:00","article_modified_time":"2025-10-10T08:44:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43023#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43023"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production","datePublished":"2025-10-10T08:44:44+00:00","dateModified":"2025-10-10T08:44:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43023"},"wordCount":285,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43023#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","keywords":["CAR-T","HKG: 2126","JW Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43023#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43023","url":"https:\/\/flcube.com\/?p=43023","name":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43023#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43023#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","datePublished":"2025-10-10T08:44:44+00:00","dateModified":"2025-10-10T08:44:45+00:00","description":"JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration (NMPA) of China has formally accepted its post\u2011marketing supplementary application for Carteyva (relmacabtagene autoleucel injection) based on an in\u2011house produced lentiviral vector. The approval marks a pivotal step in expanding Carteyva\u2019s commercial availability and addresses long\u2011standing supply\u2011chain constraints that have limited the product\u2019s global rollout.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43023#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43023"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43023#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","width":1080,"height":608,"caption":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43023#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In\u2011House Lentiviral Vector Production"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1007.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43023"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43023\/revisions"}],"predecessor-version":[{"id":43027,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43023\/revisions\/43027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43025"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}